

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 048 295 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
02.11.2000 Bulletin 2000/44

(51) Int. Cl. <sup>7</sup>: **A61K 31/216**, A61P 3/06,  
A61K 9/14, A61K 9/48

(21) Application number: **00303077.2**

(22) Date of filing: **12.04.2000**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **27.04.1999 CA 2270306**

(71) Applicant:  
**SHERMAN, Bernard Charles**  
**Willowdale, Ontario M2L 2K1 (CA)**

(72) Inventor:  
**SHERMAN, Bernard Charles**  
**Willowdale, Ontario M2L 2K1 (CA)**

(74) Representative:  
**Votier, Sidney David**  
**CARPMAELS & RANSFORD**  
**43, Bloomsbury Square**  
**London WC1A 2RA (GB)**

(54) **Pharmaceutical compositions comprising co-micronized fenofibrate**

(57) A pharmaceutical composition for oral administration comprising a co-micronized mixture of fenofibrate and a solid excipient that is not a surfactant.

**EP 1 048 295 A2**

## Description

### FIELD OF INVENTION

[0001] The present invention relates to pharmaceutical compositions for oral administration comprising fenofibrate which enable improve dissolution and bioavailability.

### BACKGROUND

[0002] Fenofibrate is practically insoluble in water. This causes fenofibrate to exhibit a low rate of dissolution in aqueous media (including gastrointestinal fluids). Which results in inadequate bioavailability (absorption into systemic circulation) after oral ingestion.

[0003] In order to make a composition comprising fenofibrate that will enable maximum bioavailability, it is necessary to incorporate into the composition a feature that increases the rate of dissolution of the drug in gastrointestinal fluids.

[0004] Several ways of increasing the rate of dissolution of drugs having low solubility in water are known in the prior art.

[0005] One approach is micronization. In this approach, the drug is milled to fine particles, typically having a mean diameter of under about 15 microns. A second approach is to include a surfactant in the composition.

[0006] For the drug fenofibrate, neither micronization alone nor use of a surfactant alone enables maximum bioavailability. US Patent 4895726 discloses that the rate of dissolution and the bioavailability of fenofibrate can be maximized by co-micronization of fenofibrate with a solid surfactant. In this process the fenofibrate is first mixed with the solid surfactant and then the mixture is micronized.

[0007] A composition made according to the invention of US Patent 4895726 is sold in Canada under the tradename Lipidil Micro and in the United States under the tradename Tricor.

A disadvantage of the technology of US Patent 4895726 is the need to include the solid surfactant in the composition. Because of the toxicity of surfactants, it is preferable to avoid use of a surfactant if possible.

Another method of increasing the dissolution rate of fenofibrate is disclosed in Canadian patent application No. 2214895. This publication discloses that the bioavailability of fenofibrate can be improved by making a solid dispersion of a disintegrant in the fenofibrate. This is done by melting the fenofibrate, blending the disintegrant into the molten fenofibrate, and resolidifying the mixture. The resulting solid can then be ground up into granules and the granules used to make the final composition. For example, the granules can be filled into two-piece hard gelatin capsules.

[0008] A disadvantage of the method of Canadian patent application No. 2214895 is that it requires the

use of specialized equipment to make the molten blend.

[0009] In view of the limitations of the prior art, it is the object of the present invention to enable increased dissolution rate of fenofibrate without the need to incorporate a surfactant in the composition, and without the need to make a molten blend.

### DESCRIPTION OF THE INVENTION

[0010] It has been found that the dissolution rate of fenofibrate can be substantially increased by co-micronization of fenofibrate with a pharmaceutically acceptable excipient that is not a surfactant. This is surprising in light of the US Patent 4895726 which teaches co-micronization only with a solid surfactant.

[0011] The term "pharmaceutically acceptable excipient" will be understood to mean any ingredient having no therapeutic activity and being nontoxic and thus suitable as an excipient.

[0012] Suitable excipients will include any of the excipients commonly used in pharmaceutical products, such as, for example, microcrystalline cellulose, lactose and starch, provided that such excipient is solid at room temperature and not a surfactant.

[0013] The ratio of the weight of the excipient to the weight to fenofibrate may be anywhere from about 1:100 to about 2:1, will preferably be from about 1:10 to about 3:2, and will most preferably be about 1:1.

[0014] The co-micronization of the fenofibrate and excipient will advantageously be carried out by mixing the fenofibrate and excipient together and then micronizing of the mixture on conventional micronization equipment, such as an air-jet mill. The mixture will preferably be micronized such that the mean particle size is less than 15 microns, more preferably less than 10 microns, and most preferably less than 5 microns.

[0015] The co-micronized powder may then be processed into solid dosage forms for oral administration (i.e. tablets or capsules).

[0016] This may be, for example, in one of the following ways:

1. Filling the co-micronized powder directly into 2-piece hard gelatin capsules.

2. Mixing the co-micronized powder with other excipients, such as, for example, fillers, binders, disintegrants, lubricants and glidants, and either filling the mixture into 2-piece hard gelatin capsules or compressing the mixture into tablets.

[0017] The invention will be more clearly understood from the following examples.

#### Example 1

[0018] 500 g of fenofibrate was mixed with 500 g of lactose monohydrate powder, and the mixture was

micronized on an air-jet mill. 2 piece hard gelatin capsules were then filled with the resultant co-micronized powder to a net fill weight of 400 mg per capsule, so that each capsule contained 200 mg of fenofibrate.

#### Example 2

[0019] 500 g of fenofibrate was mixed with 500 g of microcrystalline cellulose, and the mixture was micronized on an air-jet mill. 2-piece hard gelatin capsules were then filled with the resultant co-micronized powder to a net fill weight of 400 mg per capsule, so that each capsule contained 200 mg of fenofibrate.

#### Example 3

[0020] For comparison purposes, a quantity of pure fenofibrate was micronized using the same air-jet mill.

[0021] A sample of the pure micronized fenofibrate was then mixed with an equal weight of lactose monohydrate powder. 2-piece hard gelatin capsules were then filled with the resultant mixture to a net fill weight of 400 mg per capsule, so that each capsule again contained 200 mg of fenofibrate.

#### Dissolution Results

[0022] Capsules of examples 1 and 2 were compared to capsules of example 3 for dissolution rate.


[0023] The equipment used for dissolution testing was United States Pharmacopoeia Apparatus #2. The paddle speed was 100 rpm, and the medium was 900 mL of 0.1N sodium dodecyl sulfate water.

[0024] It was found that, in 60 minutes, over 90% was dissolved from the capsules of examples 1 and 2, whereas only 50% to 70% was dissolved for the capsules of example 3.

[0025] It is thus clear that the dissolution rate is substantially higher using fenofibrate that has been co-micronized with a solid excipient such as lactose or microcrystalline cellulose, in comparison to fenofibrate that has been micronized in pure form and then mixed with a solid excipient.

#### Claims

4. A composition as in claim 1 wherein the mean particle size of the said co-micronized mixture is less than 5 microns.
  5. A composition as in any of claims 1 to 4, wherein the ratio of the excipient to fenofibrate by weight is from about 1:100 to about 2:1.
  6. A composition as in any of claims 1 to 4, wherein the ratio of the excipient to fenofibrate by weight is about 1:10 to about 3:2.
  7. A composition as in any of claims 1 to 4, wherein the ratio of the excipient to fenofibrate by weight is about 1:1.
  8. A composition as in any of claims 1 to 5, wherein the excipient is selected from the group consisting of microcrystalline cellulose, lactose, and starch.
1. A pharmaceutical composition comprising a co-micronized mixture of fenofibrate and a solid excipient that is not a surfactant.
  2. A composition as in claim 1 wherein the mean particle size of the said co-micronized mixture is less than 15 microns.
  3. A composition as in claim 1 wherein the mean particle size of the said co-micronized mixture is less than 10 microns.



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) **EP 1 048 295 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:  
06.12.2000 Bulletin 2000/49

(51) Int. Cl.<sup>7</sup>: **A61K 31/216**, A61P 3/06,  
A61K 9/14, A61K 9/48

(43) Date of publication A2:  
02.11.2000 Bulletin 2000/44

(21) Application number: **00303077.2**

(22) Date of filing: **12.04.2000**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **27.04.1999 CA 2270306**

(71) Applicant:  
**SHERMAN, Bernard Charles**  
**Willowdale, Ontario M2L 2K1 (CA)**

(72) Inventor:  
**SHERMAN, Bernard Charles**  
**Willowdale, Ontario M2L 2K1 (CA)**

(74) Representative:  
**Votier, Sidney David**  
**CARPMAELS & RANSFORD**  
**43, Bloomsbury Square**  
**London WC1A 2RA (GB)**

(54) **Pharmaceutical compositions comprising co-micronized fenofibrate**

(57) A pharmaceutical composition for oral administration comprising a co-micronized mixture of fenofibrate and a solid excipient that is not a surfactant.

**EP 1 048 295 A3**



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 00 30 3077

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A,D	US 4 895 726 A (B.CURTET ET AL.) 23 January 1990 (1990-01-23) * claims *	1-8	A61K31/216 A61P3/06 A61K9/14 A61K9/48
A,D	EP 0 904 781 A (B.C.SHERMAN) 31 March 1999 (1999-03-31) * claims *	1-8	
A	EP 0 724 877 A (LABORATOIRES FOURNIER) 7 August 1996 (1996-08-07) * claims *	1-8	
A	WO 96 21439 A (GALEPHAR) 18 July 1996 (1996-07-18) * claims *	1-8	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 17 October 2000	Examiner Scarponi, U
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO Form 503 (3-82) (Rev.01)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 30 3077

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

17-10-2000

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4895726	A	23-01-1990	FR 2627696 A	01-09-1989
			AT 83374 T	15-01-1993
			AU 614577 B	05-09-1991
			AU 2982889 A	31-08-1989
			CA 1322529 A	28-09-1993
			DE 68903846 D	28-01-1993
			DE 68903846 T	09-06-1993
			EP 0330532 A	30-08-1989
			ES 2054040 T	01-08-1994
			GR 3006798 T	30-06-1993
			JP 1254624 A	11-10-1989
			JP 1984294 C	25-10-1995
			JP 7014876 B	22-02-1995
			NZ 228130 A	25-10-1991
EP 904781	A	31-03-1999	CA 2214895 A	27-11-1998
			AU 8607398 A	15-04-1999
			JP 11152227 A	08-06-1999
EP 724877	A	07-08-1996	FR 2730231 A	09-08-1996
			AT 194078 T	15-07-2000
			DE 69608974 D	03-08-2000
			JP 8253416 A	01-10-1996
			US 5880148 A	09-03-1999
WO 9621439	A	18-07-1996	US 5545628 A	13-08-1996
			AU 4380896 A	31-07-1996
			CA 2210985 A	18-07-1996
			EP 0801562 A	22-10-1997
			JP 10511959 T	17-11-1998

EPO FORM P0458

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82